Immune Thrombocytopenic Purpura in a Patient with Covid-19

Zulfiqar, Abrar Ahmad; Lorenzo-Villalba, Noël; Hassler, Patrick; Andrès, Emmanuel

doi:10.1056/nejmc2010472

Cited by 285 publications

(305 citation statements)

References 4 publications

Supporting

Mentioning

273

Contrasting

Unclassified

Order By: Relevance

“…In our case, PCR testing was negative on the sputum and there was no signi cant increase in IgG antibody titer over time. Among other hematological complications of Covid-19 infection, auto-immune thrombocytopenia and antiphospholipid syndrome were also described, but not present in our observation [1,[4][5].…”

contrasting

confidence: 48%

COVID-19 Infection Associated With Auto-immune Hemolytic Anemia

Capes

Bailly

Hantson

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

contrasting

confidence: 48%

COVID-19 Infection Associated With Auto-immune Hemolytic Anemia

Capes

Bailly

Hantson

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Like all viral infections, COVID‐19 may trigger a new presentation of ITP, as illustrated in a recently published case report, 38 or it may cause relapse in an existing patient. The need to actively treat ITP is unchanged from current consensus guidelines; 26 however, the additional potential burden of treatment in the context of the COVID‐19 pandemic (e.g., greater hospital contact and immunosuppression and/or thrombotic risk) needs to be carefully balanced against the risks of bleeding from ITP.…”

Section: Management Of New/relapsed Itpmentioning

confidence: 99%

Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic

et al. 2020

View full text Add to dashboard Cite

This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on immune thrombocytopenia (ITP), during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.

show abstract

“…Available data suggest most children have mild disease and that children with severe disease appear to be younger (usually less than 1 years of age) 2 or have preexisting medical conditions 3 . Mild thrombocytopenia has been seen in severe adult COVID-19 patients 4 and there is one report of immune thrombocytopenia (ITP) associated with COVID-19 in an adult patient with underlying autoimmune hypothyroidism 5 . We report a case of severe COVID-19 in a 12-year-old previously healthy child presenting with respiratory failure and severe thrombocytopenia.…”

Section: Introductionmentioning

confidence: 99%

Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia

et al. 2020

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus 2 is a worldwide pandemic. The severe morbidity and mortality associated with coronavirus disease 2019 has mostly affected the elderly or those with underlying medical conditions. We present a case of a 12-year-old girl with no past medical history who presented with fever, cough, and vomiting. Laboratory evaluation revealed severe thrombocytopenia and elevated markers of inflammation. The patient progressed to respiratory failure, and testing results for the severe acute respiratory syndrome coronavirus 2 returned positive. Because of the severity of her thrombocytopenia, she was treated with intravenous immunoglobulin and steroids with prompt improvement in platelets. The patient’s severe acute respiratory distress syndrome was managed with mechanical ventilation, inhaled nitric oxide, and then airway pressure release ventilation. After azithromycin and hydroxychloroquine were given without improvement, our patient received tocilizumab, an anti–interleukin-6 receptor antibody, and remdesivir, a broad antiviral agent, with significant clinical benefit soon afterward. Given that severe pediatric coronavirus disease 2019 is rare, we hope to inform pediatric providers on the clinical course and management considerations as this pandemic continues to spread.

show abstract

Immune Thrombocytopenic Purpura in a Patient with Covid-19

Cited by 285 publications

References 4 publications

COVID-19 Infection Associated With Auto-immune Hemolytic Anemia

COVID-19 Infection Associated With Auto-immune Hemolytic Anemia

Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic

Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia

Contact Info

Product

Resources

About